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ABSTRACT
Brain tumors can arise following deregulation of signaling
pathways normally activated during brain development and
may derive from neural stem cells. Given the requirement
for Hedgehog in non-neoplastic stem cells, we investigated
whether Hedgehog blockade could target the stem-like pop-
ulation in glioblastoma multiforme (GBM). We found that
Gli1, a key Hedgehog pathway target, was highly expressed
in 5 of 19 primary GBM and in 4 of 7 GBM cell lines. Shh
ligand was expressed in some primary tumors, and in GBM-
derived neurospheres, suggesting a potential mechanism for
pathway activation. Hedgehog pathway blockade by cyclo-
pamine caused a 40%–60% reduction in growth of adherent
glioma lines highly expressing Gli1 but not in those lacking
evidence of pathway activity. When GBM-derived neuro-
spheres were treated with cyclopamine and then dissociated
and seeded in media lacking the inhibitor, no new neuro-
spheres formed, suggesting that the clonogenic cancer stem
cells had been depleted. Consistent with this hypothesis, the
stem-like fraction in gliomas marked by both aldehyde de-
hydrogenase activity and Hoechst dye excretion (side popu-
lation) was significantly reduced or eliminated by cyclopamine.
In contrast, we found that radiation treatment of our
GBM neurospheres increased the percentage of these stem-
like cells, suggesting that this standard therapy preferen-
tially targets better-differentiated neoplastic cells. Most im-
portantly, viable GBM cells injected intracranially following
Hedgehog blockade were no longer able to form tumors in
athymic mice, indicating that a cancer stem cell population
critical for ongoing growth had been removed. STEM CELLS
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INTRODUCTION
Glioblastoma multiforme (GBM) are incurable brain cancers
that exhibit various degrees of astrocytic differentiation [1, 2]. It
has recently been proposed that GBM derive from neural stem
or progenitor cells and that signaling pathways that play a key
role in such primitive neural cells may also be required in glial
tumors [3–5]. We investigated the role of the Hedgehog (Hh)
pathway in malignant gliomas, as it plays an essential role in
cerebellar precursor cells [6–8], in growth of the cerebral cortex
[9], and in neural stem cells in the adult brain [10]. Although Hh
signaling is clearly dysregulated in a subset of human medullo-
blastomas, its role in malignant gliomas is less clear. However,
Gli1 was originally identified as a gene amplified in a human
malignant glioma, strongly suggesting such a link [11]. In
addition, Hh pathway members are expressed in primary astro-
cytoma samples [12], and Hh blockade has been shown to
inhibit the growth of a small number of glioma cell lines [9].
Hh ligands are secreted glycoproteins that bind the cell
surface receptor Patched (Ptch). Ligand binding to Ptch relieves
its inhibition of Smoothened (Smo) and allows signaling to
proceed. Smo activates the canonical Hh pathway through Gli-
dependent transcription of multiple targets, including N-myc,
cyclin D, Ptch, Gli1, and Gli2 [13, 14]. Gli proteins are large,
multifunctional transcription factors, and their activities are
tightly regulated (reviewed in [15, 16]). Hedgehog pathway
blockade has emerged as a promising therapy for multiple types
of cancer, including brain tumors and carcinomas of the pros-
tate, digestive tract, and lung [17–21]. In these latter tumors, the
Hh pathway is activated predominantly by ligands, rather than
by the Ptch mutations seen in medulloblastoma.
Because Hh signaling plays a critical role in non-neoplastic
stem cells, it has been suggested that stem-like neoplastic cells
may also be susceptible to Hh pathway blockade. The nature of
such cancer stem cells, and how one might target them thera-
peutically, has been the subject of several recent reviews [22–
26]. In brief, the cancer stem cell hypothesis suggests that only
the stem cell compartment in tumors is capable of unlimited
self-renewal and that elimination of these cells will ultimately
halt neoplastic expansion, as better-differentiated cells have
limited mitogenic capacity and will not contribute to long-term
tumor growth. The first well-documented example of cancer
stem cells was in leukemia, where only a small fraction of the
tumors identified by expression of stem-cell markers possessed
the capacity for tumor propagation [27, 28]. Similar cells have
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subsequently been isolated from brain tumors using markers
such as CD133 and side population, which were originally
developed to study non-neoplastic stem cells [29–33]. The
study of stem cells in gliomas also benefits from the capacity of
these tumors to grow as neurospheres, allowing the clonogenic
potential and differentiation capacity to be measured [33, 34]. In
this study, we demonstrate that markers of Hh pathway activity
are detected in malignant gliomas samples and that the pathway
appears to regulate the stem cell fraction in GBM cell lines.
MATERIALS AND METHODS
Clinical Specimens and Immunohistochemistry
Snap-frozen primary glioma tissues were obtained from the Depart-
ment of Pathology, Johns Hopkins University School of Medicine,
with Institutional Review Board approval. RNA was extracted from
gliomas using Trizol reagent (Invitrogen, Carlsbad, CA, http://
www.invitrogen.com) and further purified using RNeasy columns
(Qiagen, Valencia, CA, http://www1.qiagen.com) according to the
manufacturers’ instructions. The construction of the tissue microar-
ray containing high-grade astrocytomas has been previously de-
scribed [38]. Immunohistochemistry was performed on freshly cut,
deparaffinized tumor or tissue microarray sections essentially as
previously described [52]. The following antibodies were used for
immunocytochemistry: Nestin, clone MAB5326 (1:2,500; Chemi-
con, Temecula, CA, http://www.chemicon.com); glial fibrillary
acidic protein (GFAP), Z0334 (1:2,500; DAKO, Carpinteria, CA,
http://www.dako.com). Statistical analyses were performed using
GraphPad Prism4 (GraphPad Software, Inc., San Diego, http://
www.graphpad.com).
Cell Culture
The U87-MG, A172, U251, and SW1088 cell lines were obtained
from American Type Culture Collection (ATCC) (Manassas, VA,
http://www.atcc.org) and maintained in ATCC’s recommended
growth medium supplemented with 10% fetal bovine serum (FBS).
The CJ-MG and BK-MG cell lines were a kind gift from Dr. Carol
A. Kruse [53]. JHH-GBM2 was derived as follows: fresh tumor was
chopped to small pieces using sterile razor blade and then mechan-
ically triturated through a 21-gauge needle and filtered through a 40
m cell strainer (BD Falcon; BD Biosciences, Bedford, MA, http://
www.bdbiosciences.com). Cells were concentrated by centrifuga-
tion and then seeded in Dulbecco’s modified Eagle’s medium
(DMEM)/Ham’s F-12 medium supplemented with 10% FBS. The
glioblastoma-derived neurosphere line HSR-GBM1 was derived
and propagated as previously described [54]. 293T, 293T/SHH-N,
and Light2 cells were the kind gift of Dr. Phil Beachy.
The Gli reporter assay was performed in either U87-MG by
transient transfection of the Gli firefly luciferase reporter construct
or in NIH3T3 cells stably transfected with Gli firefly luciferase and
Renilla luciferase reporter constructs (Light2), as previously de-
scribed with minor modifications [55]. Briefly, Light2 cells were
plated in a 24 well plates at 7  104 cells per well in DMEM
supplemented with 10% FBS. When confluent (normally the next
day), the monolayers were washed once each with phosphate-
buffered saline (PBS) and DMEM supplemented with 0.5% FBS.
Cells were incubated overnight in a humidified incubator kept at
37°C, 5% CO2, and then growth medium was removed and mono-
layers were overlaid with conditioned medium from 293T, 293T/
Shh-N, or HSR-GBM1 and incubated for an additional 48 hours.
Gli reporter activity was quantified using the dual-luciferase re-
porter assay system (Promega, Madison, WI, http://www.promega.
com) and normalized to Renilla luciferase activity. In U87-MG, Gli
reporter activity was quantified using the luciferase reporter assay
system (Promega) and normalized to total protein.
For mRNA quantification and 3-(4,5-dimethylthiazol-2-yl)-5(3-
carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
assays, cells were plated in six-well plates (RNA) or 96-well plated
(MTS) and incubated overnight, and the monolayers were washed
once with PBS, followed by overlay with low-serum (0.5% fetal
bovine serum) media. The following day (approximately 16 hours
after serum withdrawal), medium was replaced with medium sup-
plemented with 0.5% FBS and either ethanol or cyclopamine (5 or
10 M). RNA was extracted at various time points after cyclopam-
ine addition using Qiagen RNeasy kits. MTS assays were performed
at various time points using the CellTiter96 assay (Promega) ac-
cording to the manufacturer’s instructions.
To assay neurosphere differentiation, HSR-GBM1 cells were
triturated and plated at 2  104 cells per cm2 in 10-cm2 cell culture
dishes precoated with Matrigel (BD Biosciences) diluted 1:100 in
Neurocult medium (Stem Cell Technologies, Vancouver, BC, Can-
ada, http://www.stemcell.com) without epidermal growth factor
(EGF). After attachment of cells to the plate surface, medium was
replaced with Neurocult medium lacking mitogens and heparin but
supplemented with 1% bovine calf serum (HyClone, Logan, UT,
http://www.hyclone.com). Cells were incubated for 5 days as before
and then washed, and RNA was extracted as described above.
shRNA targeting Gli1 was purchased from Sigma-Aldrich (St.
Louis, http://www.sigmaaldrich.com). pLKO.1-puro was a kind gift
from Dr. Bob A. Weinberg and Dr. Carl D. Novina [56]. U87-MG
cells were plated at 2.5  105 cells per well or 7.5  105 cells per
dish in six-well plates or 10-cm culture dishes, respectively. The
next day, medium was replaced with 2 ml of transduction medium.
Dishes were incubated overnight in humidified incubator at 37°C.
RNA was extracted from cells grown in six-well plates 48 hours
after infection. For cells grown in 10-cm dishes, medium was
replaced 72 hours postinfection with fresh medium containing 10
g/ml puromycin (Sigma-Aldrich). Cells were stained with 4,6-
diamidino-2-phenylindole, and pictures of 10 random high-power
fields were taken for each condition.
For Gli1 and Gli2 short interfering RNA (siRNA) experiments,
2  105 HSR-GBM1 cells were plated in duplicates in six-well
plate format for RNA analysis and at 1.5  104 cells per well in a
48-well format for growth assays (MTS). Cells were incubated
overnight and then transfected every other day according to the
manufacturer’s directions using RNAiFect (Qiagen) with 8 nM/well
of a nonspecific siRNA (Dharmacon, Lafayette, CO, http://www.
dharmacon.com) as negative control, Gli1 pooled siRNA, or a single
Gli2 siRNA duplex (Dharmacon) with the following oligo sequences:
Gli1 forward, 5-GGAAAUGACUGGCAAUGCAUU-3, and Gli1
reverse, 5-PUGCAUUGCCAGUCAUUUCCUU-3 for duplex 1;
Gli1 forward, 5-GCACUGGUCUGUCCACUCUUU-3, and Gli1 re-
verse, 5-PAGAGUGGACAGACCAGUGCUU-3, for duplex 2; Gli1
forward, 5-GUCCUCACUUGAACAUUAUU-3, and Gli1 reverse,
5-PUAAUGUUAAGUCGAGGACUU-3, for duplex 3; Gli1 for-
ward, 5-AGGCUCAGCUUGUGUGUAAUU-3, and Gli1 reverse,
5-PUUACACACAAGCUGAGCCUUU-3, for duplex 4; Gli2 for-
ward, 5-CGUCAACCCUGUCGCCAUUUU-3, and Gli2 reverse, 5-
PAAUGGCGACAGGGUUGACGUU-3.
Clonogenic Assays
Clonogenic assays were performed as previously described [57].
Briefly, U87-MG cells plated at 3  103 cells per well. Cells were
treated with either ethanol (vehicle [V]) or cyclopamine (5 and 10
M). Each condition was tested in triplicate, and each assay was
repeated twice with similar results. Colony number and size were
scored with the ChemiDoc-XRS imager, using the QuantityOne
software package (Bio-Rad, Hercules, CA, http://www.bio-rad.
com).
HSR-GBM1 cells were seeded in T75 cm2 culture dishes at 1
105 cells per dish. Cells were treated with either ethanol or cyclo-
pamine (10 M) in a final volume of 20 ml of Neurocult medium
(Stem Cell Technologies) supplemented with 0.002% heparin, 10
ng/ml human EGF, and 10 ng/ml human fibroblast growth factor-b
(Peprotech, Rocky Hill, NJ, http://www.peprotech.com). Dishes
were incubated upright for 7 days in a humidified incubator with 5%
CO2 at 37°C. Cells were retreated with 2 ml of medium containing
the indicated concentration of drug on days 2, 4, and 6. Seven days
after treatment, spheres were triturated and replated in T25 cm2 at
2  103 cells per dish. Subsequent sphere formation was monitored
and scored by light microscopy after 8 days. Ten random fields were
photographed for both vehicle and cyclopamine-treated conditions,
and the number of spheres over 50 m in size was scored.
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RNA Analyses
RNA levels were analyzed by real-time PCR analysis performed in
triplicate with SYBR Green reagents (Applied Biosystems, Foster
City, CA, http://www.appliedbiosystems.com), according to the
manufacturer’s instructions on an I-Cycler IQ real-time detection
system (Bio-Rad) as previously described [58]. To minimize con-
taminating genomic DNA, a 15-minute on-column DNase step
(RNase-free DNase kit; Qiagen) was included during RNA extrac-
tion. In addition, all primer sets amplify a single product of the
appropriate size and were designed to cross intron-exon boundaries.
Oligo sequences were previously described [52].
Xenograft and Side Population Assays
For side population analyses, U87-MG and C6 cells were treated for
7 days in low-serum (0.5% FBS) media containing either ethanol
(V) or cyclopamine (5 or 10 M), with medium changes every 2
days. HSR-GBM1 cells were treated in 10 ml of media, with 2 ml
of additional medium containing drug or vehicle supplemented
every 2 days. Side population analyses on treated cells were per-
formed as previously described [57]. For xenograft studies, HSR-
GBM1 cells were treated as described above, and an aliquot col-
lected from each flask following treatment was scored for viability
by Guava-PCA flow cytometry system and ViaCount reagent, ac-
cording to the manufacturer’s instructions (Guava Technologies,
Hayward, CA, http://www.guavatechnologies.com). Next, viable
cells were diluted with fresh medium and injected over 10 minutes
into the right striatum of athymic (nu/nu) mice (Harlan, Indianap-
olis, IN, http://www.harlan.com). Mice were monitored daily and
sacrificed at the first indication of tumor development (ataxia,
seizure, lethargy, or cachexia). Brains were surgically removed and
fixed immediately in formalin before submission for histological
analysis, as previously described [58].
Radiation Treatment
HSR-GBM1 cells were plated at 5 103 cells per well (in triplicate)
in 48-well culture plates and treated with either ethanol (0) or
cyclopamine (5 or 10 M). After 3 days of growth, the cultures
were irradiated at either mock (0 Gy) or 10 Gy using a Gammacell
40 irradiator equipped with a 132cesium source (MDS Nordion,
Ottawa, ON, Canada, http://www.mds.nordion.com). Cell mass was
subsequently measured on day 7 using the MTS assay (Promega),
and growth rate calculated from the first day of cyclopamine treat-
ment.
For cotreatment with cyclopamine and radiation, HSR-GBM1
cells were plated at 1  106 cells per T75 culture flask and treated
with either ethanol (0) or cyclopamine (5 or 10 M) at plating and
every other day thereafter. Cells were irradiated 4 days after plating,
and percentages of side and aldehyde dehydrogenase (ALDH)-
positive populations were determined on day 7.
RESULTS
The Hh Pathway Is Active in a Subset of Primary
GBM and Established GBM Cell Lines
To evaluate the possibility that Hh signaling is active in malig-
nant gliomas, we examined expression of pathway receptors,
ligands, and targets in primary tumor samples and in GBM cell
lines. The membrane-associated receptors Smo and Ptch were
detected in all tested samples (eight primary GBM and six
established GBM cell lines) using standard reverse transcrip-
tion-polymerase chain reaction (RT-PCR). Bands representing
Gli1 mRNA were detected in seven of eight primary GBM and
five of six established GBM cell lines. Representative data from
the analysis of three primary tumors is shown in Figure 1A. Gli1
Figure 1. Hedgehog pathway members are expressed in gliomas. (A): Ptch, Gli1, Smo, and Shh mRNAs were detected in primary glioblastoma
multiforme (GBM) samples. (B): Measurement of Gli1 and Shh mRNA using quantitative reverse transcription-polymerase chain reaction in 19
primary GBM samples and seven GBM cell lines disclosed high Gli1 expression in five tumors. (C): Gli1 immunostaining was present in all malignant
glioma samples examined, with some showing weak cytoplasmic staining (upper panel) and others showing more abundant cytoplasmic and nuclear
protein (lower panel). Endothelial cells (arrow, lower panel) were negative for Gli1 and served as internal controls. Abbreviations: ntc, no template
control; Ptch, Patched; Smo, Smoothened.
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expression is consistently correlated with Hh pathway activation
[35–37], suggesting that Hh signaling is active to some degree
in these tumors.
To more accurately quantitate the level of pathway activity,
we examined Gli1 mRNA expression by real time RT-PCR (Fig.
1B). Gli1 expression was detected in all primary tumor samples
(n  19), and Gli1 was highly expressed (Gli1/actin ratio 0.5)
in 5 of 19 (26%) of the GBM. Among the established GBM cell
lines, Gli1 was most highly expressed in U87-MG cells. In the
A172, SW1088, and U251 lines, Gli1 expression was modest,
with Gli1/actin ratios of 0.3–0.5. The Gli1/actin ratio in JHH-
GBM2, CJ-MG, and BK-MG was quite low, 0.2. We mea-
sured Shh expression to determine whether Hh activity might be
ligand-driven in some or all cases (Fig. 1B). Relatively high
levels of Shh mRNA were detected in several of the primary
GBM, including five of nine with above-median Gli1 levels.
Interestingly, the case with the highest level of Shh also had the
most prominent Gli1 expression. However, other primary tu-
mors containing Gli1 lacked Shh, suggesting that the pathway
can be activated by a ligand other than Shh or by ligand-
independent means. We did not identify Shh activity in any of
the seven adherent GBM cell lines grown in high levels of
serum, raising the possibility that these growth conditions have
a negative effect on ligand expression. Alternatively, it is pos-
sible that the Shh mRNA we detected in primary glioma sam-
ples was being generated by non-neoplastic cells and that pure
tumor cultures are therefore negative.
The presence of nuclear Gli1 protein expression in formalin-
fixed, paraffin-embedded tumor samples would also suggest that
Hh signaling is active in gliomas. We therefore examined
whether Gli1 is expressed in a nonrelated set of astrocytic
tumors using a previously described tissue microarray [38]. All
high-grade astrocytic tumors on our tissue microarray had at
least trace levels of cytoplasmic Gli1 protein (Fig. 1C, top
panel). In approximately half of the tumors, cytoplasmic stain-
ing was stronger, and Gli1 was also detected in the nucleus,
suggesting that the pathway was active (Fig. 1C, bottom panel).
Nuclear Gli1 was detected in cytologically atypical tumor cells
but not in non-neoplastic cells, such as blood vessels. We did
not observe a significant difference between the percentage of
cases with nuclear Gli1 among the grade III anaplastic astrocy-
toma (10 of 20 positive) and grade IV glioblastoma (8 of 18
positive).
Cyclopamine Decreases Gli1 Expression and Inhibits
Growth and Clonogenicity of Adherent GBM Cell
Lines
We used the Hh pathway inhibitor cyclopamine to test the
ongoing requirement for Hh signaling in glioma cells. All ex-
periments using this inhibitor were performed in low (0.5%)
serum. In U87-MG cells transfected with an Hh reporter con-
struct, cyclopamine reduced pathway activity in a dose-depen-
dent fashion, with 5 M or higher levels required to effect
significant pathway inhibition (Fig. 2A). Cyclopamine admin-
istration also inhibited endogenous Gli1 mRNA expression in
U87-MG cells by 21% at 5 M and 51% at 10 M levels (data
not shown). Gli1 mRNA expression was also inhibited by 30%
or more in the A172 and SW1088 glioma lines, but not in a
dose-dependent fashion (data not shown). Significantly, Hh
pathway inhibition using cyclopamine resulted in reduced
growth in lines with high baseline levels of Gli1 expression but
not in cells lacking significant Hh activity. In the high-Gli
U87-MG and A172 lines, growth was essentially abolished by
10 M cyclopamine, whereas the increase in cell mass in the
low-Gli CJ-MG and BK-MG lines was unaffected (Fig. 2B).
Figure 2. Hedgehog signaling is required
in established glioma cultures. (A): Effect of
48-hour cyclopamine treatment on the activ-
ity of a Gli-dependent luciferase reporter in
U87-MG. (B): The growth rate of glioma
cultures was significantly inhibited by cyclo-
pamine. (C): U87-MG cells treated with cy-
clopamine formed significantly fewer colo-
nies in agar. (D): Representative wells with
U87-MG colonies in soft agar. (E): U87-
MG: Gli1 mRNA level (top panel) and total
viable cells per hpf (bottom panel) were re-
duced by specific shRNA targeting lentivi-
rus 488 compared with either empty vector
pLKO.1-puro or the nonfunctional Gli1
shRNA 487. Two-sided t test was used
throughout. , p .05; , p .01; , p
.001. Abbreviations: hpf, high-power field;
ns, not significant; V, vehicle (ethanol) con-
trol.
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The fact that growth inhibition was observed only in tumor lines
expressing moderate or high levels of Gli1 mRNA suggests that
the effects of cyclopamine treatment are Hh pathway-specific,
rather than generally cytotoxic.
We next examined the ability of cyclopamine to block
colony formation of GBM cells. U87-MG cells seeded in soft
agar and allowed to establish initial growth were then treated
with vehicle, 5  drug, or 10 M drug for an additional 14
days, and the resulting colonies were stained and analyzed.
Colony formation was inhibited in a dose-dependent manner,
with a statistically significant 46% reduction in colonies grown
in 5 M cyclopamine (p  .03) and an approximately 90%
reduction in colonies grown in 10 M cyclopamine (p  .0001;
Fig. 2C, 2D).
To test whether the effect of cyclopamine is mediated by
reducing levels of Gli1, rather than noncanonical effects on Hh
signaling or nonspecific toxicity, we infected U87-MG cells
with lentivirus carrying short hairpin against Gli1. Gli1 mRNA
levels were reduced by 40%–50% 48 hours after virus transduc-
tion with shRNA 488, whereas a second construct (487) proved
ineffective in reducing Gli1 levels (Fig. 2E, upper panel). To test
the requirement for Gli1 only in cells containing the construct,
we took advantage of the puromycin resistance gene in the
pLKO.1-puro backbone. Consistent with an ongoing require-
ment for Gli1 in the glioma cells, introduction of Gli1 shRNA
488 and short-term puromycin selection significantly reduced
the number of cells per high-power field, whereas virus carrying
an empty vector or a nonfunctional Gli1 shRNA had no signif-
icant effect on viability (Fig. 2E, lower panel).
GBM-Derived Neurospheres Secrete and Respond to
Shh Ligand
We used GBM-derived neurospheres to further examine the role of
Hh in gliomas, including low-passage cells from tumors resected at
Johns Hopkins Hospital and grown as neurospheres (JHH-GBM3)
and a neurosphere line established at the Hospital San Raphael
(HSR-GBM1), as previously described [34]. Such GBM-derived
neurospheres demonstrate an infiltrative growth pattern similar to
that of human gliomas in vivo and have improved karyotypic
stability compared with adherent glioma lines [34, 39]. We de-
tected expression of the transcription factors Gli1 and Gli2, as well
as the receptor Smo and all three Ptch-receptor isoforms, in the
GBM-derived neurospheres (Fig. 3A). Gli1 protein is also highly
expressed in the infiltrating gliomas that arise when these cells are
injected into athymic mice (Fig. 3B). Most of the immunopositive
cells in this panel are found in or near the tumor mass and have the
morphology of neoplastic astrocytes. However, some periventricu-
lar cells and scattered cells within the brain parenchyma are also
positive, suggesting that some background staining of murine cells
is also occurring. Interestingly, unlike the seven adherent glioma
lines shown in Figure 1, the two glioma neurosphere cultures
both expressed Shh mRNA, suggesting that cultured glioma
cells are capable of generating this ligand when grown in this
fashion (Fig. 3A).
To verify that Shh expressed by GBM cells is biologically
active, we treated a Gli-luciferase reporter cell line (NIH 3T3-
Light2) that is dependent on exogenous Shh ligand with condi-
tioned medium isolated from the HSR-GBM1 neurosphere cul-
ture. As a positive control, we used conditioned medium
isolated from Shh-N-producing HEK 293 cells [40]. Condi-
tioned medium from the GBM neurospheres activated Light2
cells approximately 10-fold, whereas Shh-N had an approxi-
mately 5-fold inductive effect (Fig. 3C), indicating that highly
active Shh protein was being secreted by the GBM cells. We
next examined the ability of HSR-GBM1 cells to respond to
exogenous Shh ligand produced by Shh-N cells. HSR-GBM1
cells were dissociated and plated at low density in 1:5 or 1:50
dilutions of conditioned medium from densely confluent Shh-N
cultures. This conditioned medium induced Gli1 mRNA upregu-
lation in a dose-dependent manner, suggesting that HSR-GBM1
is capable of responding to exogenous ligand (Fig. 3D). Thus,
glioma cells growing as neurospheres appear to be capable of
secreting and responding to biologically active Shh ligand.
Hedgehog Pathway Blockade Inhibits Glioma
Neurosphere Formation and Growth and Targets
Radioresistant Cells
To examine the effects of Hh inhibition on the formation and
growth of glioma-derived neurospheres, we treated mechani-
cally separated spheres for 4 days with cyclopamine. Treatment
Figure 3. Glioblastoma multiforme (GBM)-
derived neurospheres express Hedgehog (Hh)
ligands, receptors, and targets. (A): mRNAs
for Gli1, Gli2, Smo, and Ptch1 (including the
inducible isoform Ptch1b) were all expressed
in both long-term (HSR-GBM1) and low-pas-
sage (JHH-GBM3) neurosphere cultures. (B):
Immunohistochemistry. Gli1 protein was
highly expressed in HSR-GBM1 intracranial
xenografts. Note the highly infiltrating cells
invading the CC. Arrow in inset points to a
nucleus positive for Gli1; surrounding cells
were largely negative in this region. (C): HSR-
GBM1 secretes biologically active Shh-ligand,
as evidenced by the induction of Hh reporter
activity in Light2 cells when conditioned me-
dium from the GBM neurosphere cultures was
applied. Medium isolated from 293T cells en-
gineered to secrete Shh-N was a positive con-
trol. (D): Following application of concen-
trated (1:5 dilution) conditioned media from
Shh-N secreting 293T cultures, Gli1 mRNA
levels were elevated fourfold in low-density
HSR-GBM1 cells. Two-sided t test was used
throughout. , p  .05. Abbreviations: CC,
corpus callosum; ns, not significant; ntc, no
template control; Ptch, Patched; Smo, Smooth-
ened; T, tumor; V, lateral ventricle.
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using 3 M or higher concentrations inhibited Gli1 mRNA
expression by 50%–75% compared with vehicle. Cyclopamine-
mediated Hh pathway blockade inhibited the overall growth rate
of the culture by 30%–75% in a dose-dependent fashion (Fig.
4A). This experiment was repeated three times with similar
results. Microscopic examination of these cultures showed that
few well-developed neurospheres had formed during the period
of Hh blockade, suggesting that the cells required to initiate or
sustain neurosphere growth had been inhibited or killed. Tran-
sient transfection of siRNA directed against Gli1 but not Gli2
Figure 4. Hedgehog (Hh) pathway inhibi-
tion reduces glioma neurosphere initiation
and growth. (A): The formation and growth
of HSR-glioblastoma multiforme 1 (GBM1)
neurospheres was inhibited by cyclopamine
in a dose-dependent fashion. (B): Gli1 but
not Gli2 siRNAs significantly inhibited
growth of HSR-GBM1 neurospheres relative
to non-Hh targeting siRNA control (Gli2
siRNA, p  .061). (C, D): Hh pathway
blockade affected the ability of cells to ini-
tiate sphere formation, as HSR-GBM1 cul-
tures treated for 7 days with cyclopamine
(but not vehicle) had a drastically reduced
ability to generate new spheres upon transfer
into fresh medium lacking cyclopamine. (E):
Cyclopamine modestly augmented the effect
of radiation treatment on the growth rate of
HSR-GBM1 cells. (F, G, H): Cyclopamine
treatment for 7 days significantly increased
the fraction of GFAP-expressing cells (F, G)
and reduced the fraction of nestin-expressing
cells (F, H). All images were taken at a
magnification of 60. Two-sided t test was
used throughout. , p  .05; , p  .01;
, p  .001. Abbreviations: DAPI, 4,6-
diamidino-2-phenylindole; GFAP, glial
fibrillary acidic protein; siRNA, short inter-
fering RNA; V, vehicle.
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into the neurospheres also significantly reduced cell mass after
7 days compared with control siRNA (Fig. 4B).
To more stringently test the effect of Hh blockade on the
ability of GBM cells to generate new spheres, actively growing
HSR-GBM1 cultures were treated with cyclopamine for 7 days
and then dissociated, and equal numbers of viable cells were
replated in fresh, drug-free medium. Cyclopamine pretreatment
almost completely blocked large sphere formation (Fig. 4C,
4D). Because no cyclopamine was present in the media after
replating, the lack of spheres cannot be due to ongoing
inhibition of sphere growth. Rather, these data strongly sug-
gest that a 7-day period of Hh blockade can inactivate or
remove the clonogenic stem-like cells required to initiate
sphere formation.
Figure 5. Cyclopamine depletes stem-like cells from glioblastoma multiforme (GBM) neurospheres and blocks tumor engraftment. (A): When GBM
neurospheres were forced to differentiate, mRNA levels of the proliferation marker Ki67 and the neural stem-cell markers CD133 and Nestin
decreased, along with the Hedgehog pathway targets Gli1 and Ptch1b. In contrast, markers of glial differentiation (GFAP) and neuronal differentiation
(microtubule-associated protein 2) increased. (B, C): The stem-like side population was significantly decreased by cyclopamine (two-sided t test; ,
p  .05; , p  .01). (D, E): The aldehyde dehydrogenase (ALDH)-positive subpopulation of stem/progenitor cells was also depleted by
cyclopamine. (F): The side- and ALDH-positive stem/progenitor cell subpopulations were depleted by cyclopamine and increased by radiation when
each was given alone. Cotreatment with cyclopamine and radiation depleted side- and ALDH-positive subpopulations. (G, H): HSR-GBM1 cultures
pretreated with vehicle always engrafted when either 1,000 or 10,000 viable cells counted at the end of treatment were injected into the athymic mice.
In contrast, when the same number of viable cells was injected after 7 days of treatment with 10 M cyclopamine, no detectable tumors formed (the
arrow points to degenerative changes along the injection needle tract). Log-rank analysis of Kaplan-Meier survival curves indicates that the
prolongation of survival associated with cyclopamine pretreatment is significant (p  .0001). Abbreviations: ALDH, aldehyde dehydrogenase; Cyc,
cyclopamine; DEAB, 4-(diethylamino)benzaldehyde; GFAP, glial fibrillary acidic protein; SP, side population; SSC, side scatter; T, t test; V, vehicle;
Veh, vehicle.
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Bao et al. have previously shown that stem-like CD133-
positive tumor cells in GBM are resistant to radiation therapy
[41]. However, radiation is clearly effective in eliminating at
least a subset of cells in GBM clinically, and any patients
receiving a novel chemotherapy will also likely have their tumor
irradiated. We therefore examined the effects of Hh blockade
given in combination with radiation. We treated HSR-GBM1
cultures with cyclopamine alone and in addition to 10 Gy of
radiation. As expected, both radiation and cyclopamine signif-
icantly reduced the GBM neurosphere growth rate as mono-
therapies (Fig. 4E). However, we observed a significantly lower
growth rate when 10 M cyclopamine was given in combina-
tion with 10 Gy of radiation, as compared with radiation alone.
Although 5 M cyclopamine did not significantly reduce the
growth rate, a trend in this direction was seen (p  .057,
two-sided t-test). These data suggest that Hh blockade may
target GBM cells not affected by radiation.
Cyclopamine Targets Stem-Like Glioma Cells and
Blocks Tumor Engraftment
To quantitate the effects of Hh blockade at a single-cell level,
we treated GBM neurospheres with 10 M cyclopamine for 7
days and then used immunofluorescence to examine markers of
stem/progenitor cells (nestin) and glial cells (GFAP). This re-
vealed a significant decrease in the percentage of Nestin-posi-
tive cells and an increase of more than twofold in glial differ-
entiation (Fig. 4F–4H). We also predicted that if Hh plays an
important role in maintaining stem-like cells in glioma neuro-
sphere cultures, markers of Hh activity would be reduced when
such cultures are forced to differentiate. As previously de-
scribed, when EGF, fibroblast growth factor, and heparin were
removed and 1% serum added, tumor neurospheres adhered to
the plastic culture dish and differentiated [34]. A reduction in
the expression of the proliferation marker Ki67 was observed as
cells differentiated and exited the cell cycle (Fig. 5A). In addi-
tion, we observed a 2.6-fold increase in the glial differentiation
marker GFAP and a 2.2-fold increase in the neuronal marker
microtubule-associated protein 2. Expression of the marker
CD133 was reduced more than eightfold (Fig. 5A), indicating a
loss of stem cells. As we predicted, the Hh pathway targets
Ptch1b and Gli1 were downregulated sixfold and ninefold, re-
spectively, in conjunction with tumor differentiation. Surpris-
ingly, the expression of Bmi1, a gene that is involved in stem
cell self-renewal, was increased almost twofold. One possible
explanation for this observation is that Bmi1 expression has
been reported to be maintained at high levels even in differen-
tiation-inducing conditions [42].
A more direct assessment of the effect of Hh on glioma stem
cells was performed using flow cytometric analysis of side
population, which represents a small fraction of cells within
tumors expressing ATP-binding cassette (ABC)-type transport-
ers and able to efflux both Hoechst dye and chemotherapeutic
agents [43–45]. Side population has been shown to define a
small population of stem-like cells in several established glioma
cells lines, including U87-MG [43–45] and C6 [31]. In C6
glioma cultures, it was shown that only prospectively sorted side
population cells are able to form tumor xenografts [31]. To
confirm that cyclopamine is targeting glioma stem cells, we
analyzed its effect on side population. In our experiments, side
population represented approximately 1% of the overall cellu-
larity in both the U87-MG and C6 lines (Fig. 5B, 5C). Vera-
pamil treatment totally ablated these cells, confirming that we
were measuring a bona fide side population. Cyclopamine treat-
ment dramatically diminished the side population percentage,
from 1.2% to 0.3% (5 M) and 0.2% (10 M) in C6 cells and
from 1.3% to 0.3% (5 M) and 0.2% (10 M) in U87-MG cells.
The HSR-GBM1 neurosphere line also had a small side popu-
lation (2.6%) that was reduced to 0.6% and 0.3% by 5 and 10
M cyclopamine, respectively. All experiments were repeated
at least twice, on different days, with means reported above.
Interestingly, cyclopamine also depleted the population of tumor
cells expressing ALDH, which has been shown to mark both
hematopoietic and neural stem cells [46, 47]. This expression is
assessed using the fluorescent marker Aldefluor. Cyclopamine
treatment dramatically diminished the Aldefluor-positive popu-
lation of U87-MG cells from 3.3% to 0.9% (5 M) and 0.7%
(10 M), in C6 cells from 1.4% to 0.2% (5 M) and 0.3% (10
M), and in HSR-GBM1 cells from 5.7% to 1.0% (5 M) and
0.6% (10 M) (Fig. 5D, 5E).
It has recently been reported by Bao et al. that radiation
treatment does not effectively target stem/progenitor cells, as
indicated by increased CD133-positive cell populations follow-
ing radiation exposure [41]. Radiation alone also dramatically
increased the percentages of side and ALDH-positive popula-
tions in our GBM neurospheres, supporting the concept that this
standard therapy is not able to kill cancer stem cells (Fig. 5F).
To test the ability of Hh blockade to augment radiation therapy,
we treated HSR-GBM1 cells with cyclopamine for a total of 7
days. Four days after the beginning of cyclopamine treatment,
we irradiated the cells with various doses. Side population and
ALDH-positive population percentages were determined on the
seventh day. When given alone, cyclopamine treatment reduced
the side and ALDH-positive populations from 2.6% and 4.8% to
1.6% and 1.0% at 5 M cyclopamine and to 0.4% and 0.4% at
10 M cyclopamine (Fig. 5F). Strikingly, in cultures treated
with 10 Gy radiation and cyclopamine, side and ALDH-positive
populations were dramatically reduced from 7.0% and 12.3% to
1.1% and 2.1% at 5 M cyclopamine and to 0.1% and 0.2% at
10 M cyclopamine.
Collectively, these data suggest that cyclopamine targets
glioma stem cells and might therefore prevent tumor engraft-
ment and long-term growth. To test this, HSR-GBM1 cells were
treated with vehicle or cyclopamine for 7 days in culture before
intracerebral implantation of either 1  103 (n  5 animals per
group) or 1  104 (n  3 animals per group) viable cells.
Pretreatment with cyclopamine completely inhibited tumor en-
graftment and growth, as all animals survived for the duration of
the experiment, and microscopic analysis of the injection site
failed to identify any tumor deposits (Fig. 5G, 5H). In contrast,
massive infiltrative gliomas were present in all mice implanted
with vehicle-treated cells, resulting in death as early as 2 months
following injection (Fig. 5G).
DISCUSSION
Because of their diffuse infiltration of the brain, complete sur-
gical removal of malignant gliomas is generally not possible.
Additional therapies will therefore be required to achieve a
better outcome in patients affected by these aggressive tumors.
Unfortunately, although a transient response to radiation is seen
in most patients, and some chemotherapeutic agents also appear
to reduce tumor mass, essentially all malignant gliomas, partic-
ularly GBM, rapidly recur. It has been postulated that the
recurrence of GBM following current therapies is due to the
persistent presence of a small group of stem-like cancer cells
within tumors that are relatively resistant to cell death (reviewed
in [48]). One possible mechanism for this resistance is the
expression of ABC-type transporters in these cancer stem cells,
which define a side population that can efflux chemotherapeutic
agents. Significantly, it has been shown by two groups that
small side populations are present in established glioma cell
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lines such as C6, U87-MG, and U373 and that the side popu-
lation within the C6 and U373 lines appears to be uniquely
capable of forming tumor xenografts [31, 49].
Our data suggest that the survival of stem-like side popula-
tion cells in glioblastoma is dependent on ongoing Hh pathway
activity. We first demonstrated that the components required to
transduce the Hh signal are present in the majority of GBM
samples and that mRNA expression of the pathway target Gli1
is relatively high in approximately one-quarter of cases. Forced
differentiation of GBM neurospheres reduced both stem cell and
Hh activity markers. Hh pathway blockade by cyclopamine
reduced growth in glioma lines with elevated pathway activity
but not in those with lower levels of Gli1, suggesting that when
elevated Hh signaling is detected, it is required for ongoing
tumor growth. Reduction of Gli levels using siRNA also re-
duced the viability and growth of glioma cells. Most signifi-
cantly, cyclopamine therapy dramatically reduced the side and
Aldefluor-positive populations present in GBM cells, resulting
in cultures no longer able to form colonies in vitro or xenografts
in vivo. We also show that the effects of cyclopamine and
radiation on stem-like glioma cells are quite different, with only
the former able to deplete this clinical critical population.
Our findings also point to expression of Shh ligand by GBM
cells as a mechanism for Hh pathway activation. We detected
Shh mRNA in many primary tumor samples, and the highest
level of Shh expression was found in the tumor with the most
elevated Gli1 level. In mRNA extracted from the primary tumor
samples, it is not possible to determine whether the ligand is
generated by tumor cells, entrapped non-neoplastic glia and
neurons, or stromal elements such as vessels. It is therefore
significant that we found that GBM cells grown in culture as
neurospheres secreted even larger amounts of active Shh into
their media than 3T3 cells genetically engineered to express the
ligand. This suggests that some gliomas are capable of secreting
their own ligand and are not dependent on exogenous sources.
Clement et al. have recently reported findings similar to ours
in several ways [50]. They show that Hh signaling is active in
both adherent and neurosphere-based glioma cultures and that
pathway inhibition using either cyclopamine or siRNA reduced
tumor growth, the self-renewal of glioma stem cells, and in vivo
tumorigenicity. Our studies differ in the markers used to eval-
uate cancer stem cells, as they used CD133, whereas we exam-
ined side population and aldehyde dehydrogenase-expressing
cells. We also demonstrate for the first time that malignant
glioma cells are capable of secreting biologically active Shh
ligand, suggesting antibody-mediated ligand depletion as a po-
tential therapy. Also, our results are partially consistent with the
report by Ehtesham et al., who found that Hedgehog activity is
confined to progenitor cells within gliomas [51]. However, we
detected Hedgehog pathway activity in grade IV gliomas, a
finding that is in contrast to theirs. This discrepancy may be
explained by the fact that gliomas are extremely heterogeneic,
so differences in pathway activity may relate to sample location
within the tumor. Taken together, our studies provide a strong
rationale for testing Hh inhibitors in patients with malignant
gliomas.
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